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Abstract 
 
Over the counter (OTC) phytoestrogen supplements are marketed as an alternative to 
hormone replacement therapies but may increase the risk of hormone-sensitive breast 
cancers. To begin assessing this risk, phytoestrogens were extracted from OTC 
supplements, separated using HPLC, and tested using an estrogen responsive breast 
epithelial cell line (MCF7). Results suggest lipid components of the OTC supplement 
Promensil have an antiproliferative effect on cultured breast cancer cells, though future 
research is recommended to outline the biochemical cause of this effect. 
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Background 
Introduction 
 
Research has shown that there is a link between estrogen receptor activity and breast 
cancer, a disease which affects one in eight adult, American women in their lifetime 
(DeSantis et. al, 2014). Though much research has been done to illuminate the 
relationship between human-produced estrogens and the onset of breast cancer, there 
is still much research to be done to understand the effects of phytoestrogens on the 
body, especially in relation to cancer growth.  
 
In a number of previous projects at this institution, the researchers examined the effect 
that store-bought phytoestrogen supplements had on the proliferation of breast cancer 
cells. They found that the supplements largely do have a positive proliferative effect on 
the cells, although one product was repeatedly shown to have anti-proliferative effects 
on growth. (Bitzas et. al, 2015) The goal of this project is to study whether or not 
individual phytoestrogens, lipids, or other compounds soluble in methanol in these 
supplements are responsible for the observed effects on breast cancer cell culture. 
 
To determine this, the supplements used in the previous project were extracted again. 
Using a high pressure liquid chromatography, the major components of the extracts 
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were separated and pooled fractions added to cell cultures. The effects of these 
substances on the proliferation of the breast cancer cells were measured. As many of 
the plants in the human diet contain a large variety of phytoestrogens within them, their 
effect in this regard was worth investigation. 
 
Previous MQPs 
In previous projects performed at this institution, the researchers examined the effect 
that store-bought phytoestrogen supplements had on the proliferation of breast cancer 
cells. They found that when the estrogen supplements were tested on breast epithelial 
cells, most of the supplements increased the proliferation of the cell cultures. The 
exception was that of the Promensil supplement, which did not increase the proliferation 
of the cells and, in fact, seemed to inhibit proliferation. The last group also analyzed the 
individual components of their supplements and found that one peak of note found in all 
other supplements was absent in the Promensil supplement (Bitzas et al, 2015) (Lesage 
et al, 2014).  
 
Breast Cancer 
 
In the United States, breast cancer is the second most common cancer that can occur 
in people of any gender, though it rarely occurs in men (Veronesi et. al, 2005). There 
are many types of breast cancer and the causes for all of them are currently not clearly 
understood.  The hormone, estrogen, seems to have a connection with the development 
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of certain types of breast cancer. Estrogen mediates its functions through two specific 
intracellular receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) 
(Osborne et. al, 1996). Both ERα and ERβ have nearly identical DNA-binding domains 
but their N-terminal activation function 1 regions differ greatly, meaning that there can 
be selective stimulation of the two different receptors (Katzenellenbogen & 
Katzenellenbogen, 2000).  
Estrogen 
Estrogen is a steroid hormone produced primarily in the ovaries of female vertebrates, 
but is also produced in small amounts in fat cells, the liver, the adrenal glands, and 
breast tissues (Nelson et al, 2001). It is responsible for stimulating most of the growth 
and development of the female reproductive system. There are four main types of 
estrogen produced in humans: estradiol, estrone, estriol, and estetrol (Baird et al, 1969). 
Estradiol is produced the most in females between puberty and menopause. Estradiol 
generally has the highest affinity for the receptors compared to other types of estrogen, 
meaning it has the greatest effect on estrogen related protein production (Pfaff et al, 
1973). Estrone is produced mainly by females after the onset of menopause and has a 
decreased function compared to estradiol. Menopause is essentially caused by the 
replacement of the estradiol production with estrone production (Cauley et al, 1989). 
Estriol and estetrol are only produced during pregnancy (Kaiser et al, 2000). In estrogen 
responsive cells of the female reproductive system, cell proliferation will accelerate in 
the presence of all types of estrogen in varying degrees and the steady flux of estradiol 
present in the female body between the times of puberty and menopause allow the 
8 
 
reproductive system to maintain a steady level of maintenance and function (Delemarre-
van de Waal et al, 2000). 
 
Action of estrogen on estrogen responsive cells is controlled by estrogen receptors 
(ERs) located in the cytoplasm of the cell. When ERs bind to estrogen, the receptor can 
then diffuse into the nucleus of the cell and begin to mediate protein production. There 
are two types of ERs: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). 
(Deroo et al, 2006) 
ERα (Estrogen Receptor Alpha) 
The ERα is an estrogen receptor that acts as a hormone-dependent transcriptional 
regulator for estrogen (Osborne et. al, 1996). This receptor is responsible for several 
functions, including mediating the mitogenic cancer promoting effects of estrogen (Rizza 
et. al, 2014). Assays of breast tissue cells show normal presence of alpha-receptors, 
but precursor cancer cells are shown to have a higher number of alpha-receptors in 
them (Allred et. al, 2004). Initial screening of known ER ligands shows that certain 
steroidal compounds exhibited moderate affinity and potency preference for ERα 
(Katzenellenbogen & Katzenellenbogen, 2000).  
ERβ (Estrogen Receptor Beta) 
The ERβ, like the ERα, is a cytoplasmic estrogen receptor. Unlike ERα, ERβ mediates 
the tumor suppression effects of estrogen, acting as an antagonist to the ERα effects 
(Rizza et. al, 2014). The expression of ERβ is lower in cancerous breast cells than in 
normal breast tissues, meaning that expressions levels of both ERα and ERβ have a 
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role in breast cancer carcinogenesis (Lazennec et. al, 2001). As is the case with ERα, 
there are certain estrogen compounds that have a higher affinity for ERβ than. Different 
phytoestrogen compounds show different levels of affinity to both ERα and ERβ (Morito 
et. al, 2001) but certain phytoestrogens and androgen-derived diols have a higher 
preference for ERβ than estradiols (Katzenellenbogen & Katzenellenbogen, 2000). 
Hormone Replacement Therapy 
Hormone replacement therapy (HRT) is a medical treatment in which the patient 
receives natural doses of synthetic hormones to make up for the lack of a hormone in 
the body (Laucella et. al, 1999). HRT can be used for different reasons, such as treating 
women dealing with the symptoms of menopause and people transitioning genders.  
At the beginning of the 21st century, there were about 6 million American people taking 
artificial estrogen and progestin as HRT for estrogen but the demographic has since 
declined in numbers due to studies showing a link between HRT and an increased risk 
of cardiovascular disease and breast cancer (Lerner et. al, 2011). 
Male-to-Female Transition 
As of now, there are not many studies regarding transgender individuals and their 
transition. HRT can be used to help transgender individuals to physically transition, but 
that brings to question whether transgender women undergoing this treatment will be at 
risk of breast cancer. HRT is known to have some adverse effects on menopausal 
women, but it is unknown if the same applies to transitioning women. There is one case 
of a transitioning woman with a complicated mental health history developing breast 
cancer. The patient had been taking HRT since 2002 and underwent a vaginoplasty in 
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2010 in Thailand, but did not have a breast augmentation. Though she died in 2011, the 
autopsy showed extensive metastatic tumors in her breasts and her liver. It is unknown 
whether HRT had a role in the patient’s development of breast cancer and the 
development of estrogen receptors. (Pattison & McLaren, 2013).  
Menopause 
Menopause is a condition that women undergo when they stop having a regular 
menstruation cycle due to a decrease in production of estradiol and progesterone. The 
average age range where menopause occurs is 40 to 50 years old and it is a natural 
biological condition that women experience. (Nelson, 2008) 
 
The symptoms menopausal women experience vary by individual. Some common 
symptoms include hot flashes, vaginal dryness, and night sweats, among others 
(Nelson, 2008). Complications can arise from menopause due to the declining 
production of reproductive hormones, specifically estradiol. These complications include 
cardiovascular disease, osteoporosis, and pelvic organ atrophy (Laucella et. al, 1999). 
These symptoms and complications can be reduced and alleviated with the use of HRT 
by replacing the declining estradiol and progesterone in the body. 
 
However, there are risks associated with using HRT to alleviate menopause symptoms. 
While HRT can alleviate the symptoms of menopause, there is also an increased risk of 
breast cancer. Cells in the body, particularly breast tissue cells, are stimulated by the 
presence of estrogen (Laucella et. al, 1999). HRT does not create de novo breast 
cancerous cells, rather, HRT stimulates pre-cancer cells to grow (Dietel, 2010). These 
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pre-cancerous cells may have active estrogen receptors, specifically ERα, that are 
stimulated by HRT to proliferate (Allred et. al, 2004). In the last decade, there has been 
a decline of breast cancer rates and studies have shown that this decline has a positive 
correlation with the declining use of HRT (Neutel & Morrison, 2010). 
Phytoestrogens 
Phytoestrogens are a class of compounds which plants naturally produce. These 
compounds are either structurally or functionally similar to the estrogen molecule, 
allowing them to potentially act as if they were estrogen within animal cells. There are 
many differing types of phytoestrogens grouped together based on their general 
structure. Varieties of phytoestrogens include flavonoids, isoflavonoids, and lignans. 
(Patisaul & Jefferson, 2010) 
 
There is a wide variety of potential uses for phytoestrogens in a medical sense. They 
have been claimed to aid in relieving menopausal symptoms as a hormone 
replacement. They may prevent the development of osteoporosis due to the effects 
estrogen has on bone density. They have also been thought to improve cardiovascular 
health and prevent heart disease. However, many of these claims have yet to produce 
definitive results due to widely varying dosage, composition, compounds, and duration 
of use across the various studies into their effects. In addition, phytoestrogens may 
have many negative effects on the human body. There has been much debate in this 
topic over the years as to whether or not phytoestrogens affect breast cancer 
proliferation, and if they do, whether that effect is positive or negative. There is evidence 
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to suggest that phytoestrogens can disrupt natural hormone levels and ovulation in both 
animals and humans.(Patisaul & Jefferson, 2010) 
Isoflavonoids 
Isoflavonoids are mostly found in the subfamily Papilionoideae, which is within the 
family Lefuminosae. (Dixon, 2004) This form of phytoestrogen was the first to be 
discovered, being found in a study devoted to the negative effects that clover seemed to 
be having on cattle and sheep. These compounds are derived from flavanones. Most 
phytoestrogens that are used in dietary supplements tend to be simple isoflavones, with 
the exception of coumestrol. (Dixon, 2004) There are relatively few plants in a typical 
human diet that produce isoflavonoids. The main sources in the human diet of these 
phytoestrogens are soybeans, chickpeas, and alfalfa sprouts. Some specific 
isoflavonoids have decreased levels of estrogen-like effects, such as those that have 
undergone O-methylation. (Dixon, 2004) 
 
Methylated isoflavones which have undergone isoprenylation may have greater effects 
similar estrogen, but are generally too uncommon in the human diet to be considered 
statistically important. (Dixon, 2004) The isoflavonoids formononetin and biochanin A 
have been shown to have lowered estrogenic effects when compared to daidzein and 
genistein, phytoestrogens shown to have a proliferative effect on estrogen responsive 
breast cancers in concentrations lower than 10µL/mL (de Lemos, 2001). Of special 
interest within the isoflavonoids is coumestrol. Coumestrol shows strong estrogenic 
activity, showing effects similar to that of estradiol. Coumestrol also shows a greater 
affinity for binding to the ER than genistein does. (Dixon, 2004) 
13 
 
Flavonoids 
When compared to their isoflavonoid cousins, flavonoids tend to show negligible or low 
estrogenic activity. (Dixon, 2004) This is especially common among those which are 
typically a part of the human diet. Despite this, some flavonoids, especially flavones, are 
better than isoflavonoids at inhibiting the aromatase cytochrome P450 pathway which 
helps to convert androgens to estrogens. (Dixon, 2004) Within the flavonoid family, one 
compound of special interest is 8-prenylnaringenin. This compound, produced by hops, 
is one of the more potent flavonoids in a phytoestrogen sense. It can show ER-
mediated activity at a magnitude lower concentration than its parent flavonoid. (Dixon, 
2004) 
Lignans 
Defined as dimeric phenylpropanoid compounds, lignans function in a wide distribution 
within the plant kingdom as a defense mechanism. (Dixon, 2004) In the human diet, 
they are mostly present in cereals and grains, as well as berries and garlic. While not 
typically phytoestrogens themselves, these compounds can be converted to 
phytoestrogens by symbiotic microflora in the proximal colon. (Dixon, 2004) 
Other Phytoestrogens 
There are several other assorted compounds found in many plants used for medicinal 
purposes and found naturally in the human diet that may have significant estrogenic 
activity. (Dixon, 2004) For example, fresh corn was discovered to have a mitogenic 
compound after corn cob bedding was found to interfere with the estrus cycle and 
sexual behavior of rats. (Dixon, 2004) This compound stimulates proliferation of breast 
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cancer cells of both the ERα and β varieties. While no specific compound was identified, 
some preliminary studies suggest that safflower seeds can protect against ovariectomy-
induced bone loss in rats. (Dixon, 2004) Other interesting phytoestrogens include the 
chalcone and isoflavonoids in licorice root, the phenylbutanone glucoside lindleyin found 
in rhubarb, and several bioactive triterpenoid compounds in ginseng. (Dixon, 2004) 
Cell Line 
In order to gather the data for the experiments performed in this study, it was necessary 
to maintain a cell line to perform these tests on. In this study, the cell line used was an 
MCF7 ATCC line. Obtained from a 69 year old Caucasian female with adenocarcinoma, 
these cells were gathered from a metastatic site from pleural effusion in the lungs. 
(MCF7 (ATCC HTB-22)) These cells are an epithelial line that is adherent. When the 
cells are examined with a karyotype, the modal number of chromosomes is 82, with 
individual specimens ranging from 66 to 87 chromosomes. (MCF7 (ATCC HTB-22)) 
Crucially, these cells are estrogen-responsive and process estradiol through standard 
receptor pathways, meaning that substances that are estrogen-like should upregulate 
the growth of the cells. (MCF7 (ATCC HTB-22)) 
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Methods 
Media 
MCF-7 cells were incubated at 37°C and 5% CO2 in a humidified incubator  in DMEM 
with10% volume Fetal Bovine Serum, 300 μg/ml PenStrep, 300 μg/ml glutamine + 2 
ng/ml insulin as outlined in Hamelers et al, 2003. Cells used for proliferation assays 
were harvested at 40-60% confluence with trypsin.  Prior to use in the MTT assay, cells 
were maintained as described above. When they reached 60-70% confluence, the cells 
were plated in 36 wells of a 96 well culture plate with 104 cells/well. The cells were 
incubated in Phenol red-free medium with 5% dextran-coated charcoal-treated (DCC) 
serum for 24 hours to allow the cells to adhere to the plate. After 24 hours passed, the 
serum was replaced with phenol red-free, DCC serum-stripped media containing 0.2% 
bovine serum albumin, 10ug/mL of transferrin, and 30 nM sodium selenite and cells 
were incubated for another 24 hours. The serum-stripped media allowed the cells to 
synchronize their cell cycles in order to remove confounding factors from cells in 
different stages of the cell cycle. 
 
Extraction of supplements 
Supplement extractions were done on the phytoestrogen supplements following the 
procedure outlined in Setchell et. al (2001). Briefly, supplement samples were added to 
a 250 mL round bottom flask and mixed with 80 mL of 80% methanol. The mixture in 
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the flask was refluxed with round bottom flask and a fractional column for one hour in 
boiling methanol. All extracts were filtered and stored in a -20 °C. 
 
For this experiment, extracts of Oregon’s Wild Harvest Red Clover (manufactured by 
Oregon’s Wild Harvest, Lot # 104214RCL) and Promensil (manufactured by Natrol, Lot 
# 16156B) were used. One 80 mg tablet of Promensil was crushed in a sterile mortar 
and pestle while three 350 mg capsules of Wild Harvest were used. These quantities for 
both brands of supplements represent one recommended daily dose. 
 
High Performance Liquid Chromatography (HPLC) 
HPLC was performed on the extracts following the same procedure that was used for 
the previous MQP (Caron, 2007). Briefly, sample extracts were separated using a C18 
250 X 4.6 mm column with a linear gradient of 10mM ammonium acetate-0.1% 
trifluoroacetic acid and 100% acetonitrile. The column was started with 100% 
acetonitrile and the solvent’s percent composition gradually changed to 100% 
ammonium acetate-0.1% trifluoroacetic acid by the end of the run. For the first 2 
minutes, the column was washed with with a solution of 10 mM ammonium acetate and 
0.1% of trifluoroacetic acid at 100% concentration. Over the next 22 minutes, the 
column was washed with a linear gradient of 10 mM ammonium acetate-0.1% TFA and 
100% acetonitrile. Over the this time period, the percentage of 10 mM ammonium 
acetate-0.1% TFA in the solution changed from 100% to 50% while the percentage of 
acetonitrile changed from 0% to 50%. Following this, for 5 minutes, the column was 
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washed with a 50% ammonium acetate-TFA and 50% acetonitrile solution. The 
remainder of the time in the procedure comprised of the column being washed with 
100% ammonium acetate-TFA. The HPLC instrument operated for a total of 36 minutes 
with the flow rate being 1 mL/minute of solution eluded. A chromatogram of the samples 
was generated by measuring the absorbance (in mAU, or micro absorbance units) of 
the samples at 260 nm over the course of the HPLC. To test if the solvent had any 
effect on the cells, the HPLC instrument was run without any samples loaded in and the 
elution was collected in the same fractions as the elution for the supplements. The 
samples from this run were used in the cell culture experiment as outlined in the 
following section, Methods, MTT Assay. 
MTT Assay 
As described above, cells were counted, trypsinized and plated in 96 well plates at a 
concentration of 1x103 cells per well in 100μl of media with serum. Cells were given 24 
hours to adhere before media was aspirated and replaced with 100 μL of serum-starved 
media. This allowed the cells to all come to phase G0 in their growth cycle. After 24 
hours, this media was then replaced with 100μl of charcoal stripped serum media 
(DMEM + 10% volume Charcoal Stripped FBS + 300 μg/ml PenStrep + 300 μg/ml 
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Glutamine) along with 10μl of sample as outlined in Figure 1.
 
Figure 1: Diagram for the Layout of 96-Well Plates Used in Assay 
Charcoal stripped serum was used for this step as this serum does not contain any 
lipids and therefore no hormones such as estradiol. After 24 hours incubation, 10μL of 
CellTiter 96 Aqueous One solution (manufactured by Promega) was added to each well, 
incubated for 1 hour and absorbance was read at both 450 and 570 nm as the optimum 
wavelength to measure the assay is 490nm and the project team did not have access to 
this wavelength filter. 
 
Data Analysis 
Once the data was read, an average was obtained for the absorbance of each triplicate. 
For each non-control triplicate, its average was expressed as a percentage of the 
positive (estradiol added) control triplicate average. The percent control for each sample 
condition was averaged across all test sets. A standard deviation was taken for each of 
these averages, and from the standard deviation a standard error was taken. This 
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process was then repeated using the negative (no extract added) controls. The data 
was separated between what wavelength was used to take the data. 
Results 
High Performance Liquid Chromatography (HPLC) 
The HPLC procedure outlined in the methods section was used on extract samples of 
Promensil and Wild Harvest twice, each using the same sample. For each supplement 
during their HPLC runs, the eluate was collected in test tubes with each tube collecting 
a five minute interval throughout the entire HPLC run. 
 
Figure 2 and Figure 3 show the two chromatograms for Promensil. The x-axis shows 
the time and the y-axis is the absorbance in micro absorbance units (mAU). The nearly 
identical traces show a number of large peaks between 15 and 36 minutes. 
 
Figure 2: Chromatogram for Promensil (1st run) 
20 
 
Chromatogram of first HPLC run for Promensil. Eluate was collected in test tubes each collecting five 
minute interval throughout the entire run. X- axis shows time (min.) and y-axis shows absorbance (mAU) 
 
 
Figure 3: Chromatogram for Promensil (2nd run) 
Chromatogram of second HPLC run for Promensil. Eluate was collected in test tubes each collecting five 
minute interval throughout the entire run. X- axis shows time (min.) and y-axis shows absorbance (mAU) 
 
Figures 4 and 5 show the chromatograms for Wild Harvest. 
 
Figure 4: Chromatogram for Wild Harvest (1st run) 
Chromatogram of first HPLC run for Wild Harvest. Eluate was collected in test tubes each collecting five 
minute interval throughout the entire run. X- axis shows time (min.) and y-axis shows absorbance (mAU) 
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Figure 5: Chromatogram for Wild Harvest (2nd run) 
Chromatogram of second HPLC run for Wild Harvest. Eluate was collected in test tubes each collecting 
five minute interval throughout the entire run. X- axis shows time (min.) and y-axis shows absorbance 
(mAU) 
 
Due to the significant differences seen between the two runs, of the two Wild Harvest, a 
third run was performed.  This chromatogram (not shown) was nearly identical to that 
shown in Figure 5. Due to the discrepancies seen in the first run (Fig.4), the extracts 
from it were discarded and those from the second set of Wild Harvest runs used for all 
subsequent experiments. 
MTT Assays 
The MTT assays were conducted as described in the MTT assay methods section. 
HPLC fractions were collected at 5 minute interval and pooled together with half 1 
comprised of the pooled samples collected from 0-15 minutes and half 2 from 15-36 
minutes. An additional sample was comprised of all of the fractions from each run and 
22 
 
labeled as “pooled”. The absorbance reading is measured in micro absorbance units 
(mAU). Appendix B shows all of the raw data of MTT assay results for the plates. 
 
HPLC fractions were collected at 5 minute interval and pooled together. Half 1 = pooled 
samples collected from 0-15 min; half 2 = pooled samples collected from 15-36 min; 
total = all of the fractions from total HPLC run. Average values from five MTT assays of 
Promensil and Wild Harvest were expressed as a percent of the negative control where 
no samples were added.
 
Figure 5: MTT Assays Expressed as Percent of Negative Control (No Extract 
Added) 
 
 
Figure 5 shows the average values from five MTT assays of Promensil and Wild 
Harvest expressed as a percent of the negative control, which had nothing added to the 
growth media. If the absorbance of a sample is shown as 100%, then the sample would 
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have the same absorbance readings as the control meaning that the supplement had no 
effect on cell proliferation relative to the untreated control. For Promensil, the percent 
control for the total fraction was 83.8%, for the 0 to 15 minute fraction 88.0%, and for 
the 16 to 36 minute 77.4%. For Wild Harvest, the total fraction value was 82.0% of the 
control value, the 0 to 15 minute fraction 85.4%, and the 16 to 36 minute fraction 86.2%. 
These data are graphically represented in Figure 5. As seen in Figure 5, both Promensil 
and Wild Harvest samples show a lower absorbance reading than the negative control. 
The second half sample from the Promensil extract resulted in the lowest value, 
indicating the most inhibition of proliferation average, about 23%. 
 
Figure 6: MTT Assays Expressed as Percent of Positive Control (Estradiol added) 
HPLC fractions were collected at 5 minute interval and pooled together. Half 1 = pooled 
samples collected from 0-15 min; half 2 = pooled samples collected from 15-36 min; total = all of 
the fractions from total HPLC run. Average values from five MTT assays of Promensil and Wild 
Harvest were expressed as a percent of the positive control, estradiol. 
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Figure 6 shows the MTT assays of Promensil and Wild Harvest samples of the plates 
expressed as a percent of the positive control (samples treated with estradiol).  As with 
the case in Figure 5, if the sample value is 100% then it would have the same 
absorbance as the positive control, meaning that the sample and the positive control 
had similar effects on growth of the MCF7 cells. For Promensil, the total fraction value 
was 84.8% of positive control, the 0 to 15 minute 87.4%, and the 16 to 36 minute 
fraction 78.0%. For Wild Harvest, the total fraction value was 84.2% of the positive 
control, the 0 to 15 minute fraction 88.4%, and the 16 to 36 minute fraction 86.8%. 
Again the second half sample from Promensil has the largest impact, resulting in a 22% 
inhibition of proliferation relative to the estradiol treated sample. 
 
For both Figure 5 and 6, the averages of the solvent control were not shown due to the 
averages being similar to the averages of the positive and the negative control, thus 
clarifying that the solvent does not have an effect on the growth of the cells. Appendix A 
shows the graphs with the averages of solvent control included. 
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Discussion and Recommendations 
This study was performed to test the proliferative effect of OTC phytoestrogen 
supplements on breast cancer cell culture. The data showed that Promensil samples 
consistently showed lowered cell proliferation relative to both untreated and estradiol 
treated cells. This is consistent with previous data suggesting that the OTC product has 
anti-proliferative effects on breast cancer cells. The results using the Wild Harvest 
samples were less consistent and generally showed little or no overall effect on cell 
growth, as none of the data were statistically significant. 
 
Of note amongst the Promensil samples was the 15-36 minute time fraction. Compared 
to the rest of the samples, this portion of the Promensil sample seemed to have the 
greatest antiproliferative effect of all tested fractions, including the Wild Harvest 
fractions. Whereas all other phytoestrogen supplement fractions tested resulted in 
effective cell counts that were 85-90% of control samples, the second fraction of 
Promensil values were 77.4% of the negative control and 78.0% of the positive control. 
While no analysis of the significance of this was done due to the small sample size, this 
is noticeably lower than any other sample tested and bears future attention. 
 
While the Wild Harvest samples had an average absorbance under 90% of that of either 
control, the standard error for the Wild harvest samples was very high. This can be 
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attributed to one Wild Harvest sample out of the five having an absorbance much lower 
than that of the rest of the plate in any other samples. The absorbance of this particular 
plate can be found in Appendix B. If these data were omitted from the analysis, it seems 
likely that Wild Harvest would have had no demonstrable effect at best, or potentially 
even a somewhat proliferative effect.  Again, these data bear repeating. 
 
The highly irregular first HPLC run of the Wild Harvest sample was not explored further 
by this team, but could have been caused by any number of issues. It could have been 
that the sample had settled to the bottom of the vial used to inject the sample into the 
HPLC instrument, resulting in not all of the compounds being injected into the column.  
Alternatively, the results of that specific run could have been due to contamination in the 
line from an experiment performed by another group using extracts of different 
substances. Regardless, the result was assumed to be a form of error rather than a 
valid result and was summarily ignored. 
 
It is the recommendation of this team that future experiments and MQPs should focus 
on the proliferative effects of the Promensil samples, specifically on extracts collected in 
the 15-36 minute eluted HPLC fraction. The samples containing fractions from the 
second half of the Promensil chromatography consistently show lower absorbance 
against the absorbance of estradiol samples. This would seem to indicate that there is 
some compound in the Promensil supplement which may suppress the proliferation of 
estrogen responsive cancer cells. Future experimenters may wish to plate and perform 
similar experiments as outlined in the Methods, MTT Assay section, but instead, plate 
wells with Promensil HPLC samples from shorter fraction times - ie. have triplicates of 
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0-5 minutes, 5-10 minutes, 10-15 minutes, etc. for the Promensil samples.  
 
The fact that the same fraction of Promensil resulted in similar effects on cells both 
untreated cells and cells treated with estradiol may suggest that the effect is not being 
mediated through the estrogen receptor. The use of T47D KBluc cells which have a 
luciferase gene under the control of the estrogen response element would allow further 
analysis in this regard. 
 
Additionally, further identification of the peaks for these extracts would be of use in 
future projects. Previous groups have made efforts at identifying several of the peaks as 
phytoestrogens, but these only account for a select few of the peaks in each sample. 
Many of the peaks still remain unidentified, and a study specifically focused on 
identifying all of the compounds in the samples could be of benefit for future studies 
focused on only analyzing the effects of specific peaks. 
 
In addition, there are limitations with the methodology that was used in this project for 
measuring cell proliferation in the wells of the plate. The assay used to measure cell 
proliferation measures absorbance based on the total activity of the mitochondria. 
Strictly speaking, this is not a direct measure of proliferation, but can be indicative of it. 
If possible, it might be useful to use a different assay in future iterations of the project 
that offer a more direct measure of the quantity of cells in a well. This would come with 
other issues, as previous iterations of the project have used this assay, making it harder 
to compare results between research teams. However, it would offer a more accurate 
way to tell proliferative effects of these substances.  
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Appendix A 
Additional Assay Analysis Figures 
 
Figure 7: MTT Assays at 570 nm Expressed as Percent of Negative Control (No 
Extract Added), Including Solvent Control 
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Figure 8: MTT Assays at 570 nm Expressed as Percent of Positive Control 
(Estradiol Added), Including Solvent Control 
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Figure 9: MTT Assays at 450 nm Expressed as Percent of Positive Control 
(Estradiol Added), Including Solvent Control 
 
 
Figure 10: MTT assays compared to Positive Control (Estradiol) at 450 nm, 
Including Solvent Control 
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Appendix B 
Calculated Data for MTT Assays 
 
 
Negative Control 570 
 
Blank 
Total 
Blank 
First 
Blank 
Second 
Prom 
Total 
Prom 
First 
Prom 
Second WH Total WH First 
WH 
Second 
First 
Plate, % 
of Control 60 71 72 85 80 77 83 112 106 
Second 
Plate, % 
of Control 90 91 89 90 87 84 44 69 43 
Third 
Plate, % 
of Control 107 80 80 55 55 49 74 63 70 
Fourth 
Plate, % 
of Control 115 96 117 79 93 77 105 73 65 
Fifth 
Plate, % 
of Control 117 120 98 110 125 100 104 110 147 
Average 
% 97.8 91.6 91.2 83.8 88 77.4 82 85.4 86.2 
Standard 
Deviation 
23.6579
7963 
18.6091
3754 
17.39827
578 
19.86705
816 
25.23885
893 
18.44722
201 
25.10975
906 
23.64952
431 
40.82523
729 
Standard 
Error 
10.5801
7013 
8.32225
9309 
7.780745
466 
8.884818
512 
11.28716
085 
8.249848
483 
11.22942
563 
10.57638
88 
18.25760
116 
 
Table 1: Raw Data for Plates Read at 570 nm, Compared to Negative Control 
 
 
Positive Control 570 
 
Blank 
Total 
Blank 
First 
Blank 
Second 
Prom 
Total 
Prom 
First 
Prom 
Second WH Total WH First 
WH 
Second 
35 
 
First Plate, 
% of 
Control 80 94 95 113 106 102 110 149 141 
Second 
Plate, % of 
Control 88 88 86 88 84 82 43 67 42 
Third 
Plate, % of 
Control 134 100 100 69 69 61 92 79 88 
Fourth 
Plate, % of 
Control 116 97 118 80 94 78 106 73 65 
Fifth Plate, 
% of 
Control 79 80 66 74 84 67 70 74 98 
Average % 99.4 91.8 93 84.8 87.4 78 84.2 88.4 86.8 
Standard 
Deviation 
24.470
39027 
7.949842
766 
19.078
78403 
17.28293
956 
13.70401
401 
15.82719
179 
27.84241
369 
34.1438
135 
37.23842
102 
Standard 
Error 
10.943
49122 
3.555277
767 
8.5322
91603 
7.729165
544 
6.128621
378 
7.078135
348 
12.45150
593 
15.2695
776 
16.65352
815 
 
Table 2: Raw Data for Plates Read at 570 nm, Compared to Positive Control 
 
 
Negative Control 450 
 
Blank 
Total 
Blank 
First 
Blank 
Second 
Prom 
Total 
Prom 
First 
Prom 
Second WH Total WH First 
WH 
Second 
First Plate, 
% of 
Control 76 84 86 95 91 92 94 112 106 
Second 
Plate, % of 
Control 87 83 81 84 80 80 54 81 55 
Third 
Plate, % of 
Control 119 97 100 79 75 68 89 79 84 
Fourth 
Plate, % of 
Control N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Fifth Plate, 
% of 
Control N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Average % 94 88 89 86 82 80 79 
90.66666
667 
81.66666
667 
Standard 
Deviation 
22.3383
079 
7.81024
9676 
9.84885
7802 
8.185352
772 
8.185352
772 12 
21.79449
472 
18.50225
212 
25.57994
006 
36 
 
Standard 
Error 
9.98999
4995 
3.49284
9839 
4.40454
3109 
3.660601
044 
3.660601
044 
5.366563
146 
9.746794
345 
8.274458
693 
11.43969
697 
 
Table 3: Raw Data for Plates Read at 450 nm, Compared to Negative Control 
 
 
Positive Control 450 
 
Blank 
Total 
Blank 
First 
Blank 
Second 
Prom 
Total 
Prom 
First 
Prom 
Second WH Total WH First 
WH 
Second 
First 
Plate, % 
of Control 99 111 102 111 96 100 102 120 94 
Second 
Plate, % 
of Control 86 81 80 83 78 78 53 80 55 
Third 
Plate, % 
of Control 130 106 110 87 82 74 97 86 91 
Fourth 
Plate, % 
of Control N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Fifth 
Plate, % 
of Control N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Average 
% 105 
99.333
33333 
97.33333
333 
93.66666
667 
85.33333
333 84 84 
95.33333
333 80 
Standard 
Deviation 
22.6053
0911 
16.072
75127 
15.53490
693 
15.14375
559 
9.451631
253 14 
26.96293
753 
21.57158
625 
21.70253
441 
Standard 
Error 
10.1094
0156 
7.1879
52884 
6.947421
584 
6.772493
386 
4.226897
996 
6.260990
337 
12.05819
224 
9.647106
647 
9.705668
447 
 
Table 4: Raw Data for Plates Read at 450 nm, Compared to Positive Control 
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Appendix C 
Raw Absorbance Data from MTT Assays 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
A 0.282 0.199 0.153 0.126 0.029 0.029 0.03 0.03 0.031 0.031 0.033 0.031 
B 0.611 0.559 0.131 0.148 0.029 0.03 0.03 0.03 0.03 0.032 0.033 0.031 
C 0.031 0.032 0.031 0.031 0.031 0.031 0.03 0.03 0.03 0.033 0.033 0.033 
 
Table 5: First Assay Absorbance Raw Data at 570 nm 
 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
A 1.104 1.101 0.548 1.384 0.825 1.488 0.551 0.853 0.807 0.618 0.428 0.527 
B 1.028 0.893 1.174 1.043 1.044 0.997 1.302 1.09 0.859 1.124 0.677 0.538 
C 0.051 1.18 1.522 1.251 1.204 1.248 0.685 1.04 0.796 1.619 1.215 1.011 
 
Table 6: Second Assay Absorbance Raw Data at 570 nm 
 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
38 
 
A 0.87 0.954 0.9 1.013 0.984 0.982 0.936 0.915 0.749 0.917 0.911 0.872 
B 1.187 0.687 1.053 1.082 0.914 1.048 0.669 0.722 0.729 0.742 0.616 0.596 
C 0.811 0.986 1.037 1.323 0.884 0.848 0.67 0.51 0.469 0.893 0.735 0.934 
 
Table 7: Third Assay Absorbance Raw Data at 450 nm 
 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
A 0.751 0.766 0.722 0.811 0.745 0.753 0.707 0.666 0.54 0.692 0.643 0.689 
B 1.078 0.462 0.876 0.854 0.657 0.769 0.374 0.461 0.48 0.448 0.384 0.36 
C 0.67 0.777 0.848 1.017 0.6 0.475 0.295 0.257 0.194 0.697 0.547 0.709 
 
Table 8: Third Assay Absorbance Raw Data at 570 nm 
 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
A 1.233 1.358 1.358 1.105 1.241 1.241 1.415 1.153 1.229 0.818 1.564 0.629 
B 1.513 1.471 1.349 1.235 1.151 1.067 1.011 1 0.996 0.76 1.039 0.865 
C 1.469 1.46 1.361 1.338 1.087 1.11 1.122 1.2 1.126 0.692 0.829 0.844 
 
Table 9: Fourth Assay Absorbance Raw Data at 450 nm 
 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
39 
 
A 1.373 1.659 1.464 1.368 1.605 1.526 1.647 1.431 1.506 0.771 1.636 0.585 
B 1.801 1.675 1.508 1.333 1.408 1.348 1.286 1.238 1.215 0.709 0.916 0.79 
C 1.636 1.614 1.496 1.63 1.354 1.395 1.413 1.511 1.319 0.636 0.768 0.688 
 
Table 10: Fourth Assay Absorbance Raw Data at 570 nm 
 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
A 0.324 0.307 0.265 0.268 0.291 0.308 0.381 0.318 0.332 0.298 0.469 0.373 
B 0.368 0.304 0.294 0.269 0.303 0.294 0.324 0.33 0.351 0.328 0.364 0.396 
C 0.391 0.315 0.273 0.289 0.319 0.328 0.329 0.341 0.309 0.388 0.383 0.379 
 
Table 11: Fifth Assay Absorbance Raw Data at 450 nm 
 
 
- + Solvent 
MeOH 
Total 
MeOH 
0-15 
MeOH 
16-36 
Prom 
Total 
Prom 
0-15 
Prom 
16-36 
WH 
Total 
WH 0-
15 
WH 
16-36 
A 0.214 0.196 0.146 0.158 0.174 0.185 0.257 0.204 0.196 0.183 0.337 0.271 
B 0.264 0.19 0.154 0.143 0.184 0.172 0.194 0.196 0.206 0.191 0.253 0.281 
C 0.284 0.186 0.15 0.154 0.182 0.189 0.197 0.206 0.183 0.258 0.261 0.252 
 
Table 12: Fifth Assay Absorbance Raw Data at 570 nm 
